# Florent Gros

> Florent Gros is a Series C investor at Amyl Therapeutics backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Amyl Therapeutics](https://shizune.co/investors/profile/amyl-therapeutics)
- Location: Antwerp, Belgium
- Total investments: 12
- Last investment: Dec 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/florent-gros-087aba1a2

Florent Gros is a Series C investor at Amyl Therapeutics in Antwerp focused on Biotechnology and Health Care. Florent Gros is the Chairman & Founder at Amyl Therapeutics. He attended University of Mulhouse.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 58% |
| Health Care | 6 | 50% |
| Therapeutics | 4 | 33% |
| Health Diagnostics | 2 | 17% |
| Mobile | 1 | 8% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 42% |
| Series B | 4 | 33% |
| Seed | 1 | 8% |
| Series A | 1 | 8% |
| Series D | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 17% |
| United States | 2 | 17% |
| Iceland | 1 | 8% |
| Switzerland | 1 | 8% |
| The Netherlands | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GEMMABio | GEMMABio is a therapeutics company that supports the rare disease community. | $34M | Seed | Dec 23, 2024 |  |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $100M | Series C | Jun 13, 2022 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M | Series C | May 04, 2021 |  |
| Anokion | Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can betranslated to virtually any protein in numerous clinical indications. | $40M | Series B | Sep 11, 2019 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $23.3M | Series B | Jan 04, 2018 |  |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $35M | Series D | Jan 23, 2017 |  |
| Myopowers Medical Technologies | Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area.The company focus is the development of ARTUS, a new and unique implantabledevice for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation.ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market. | $4.9M | Series C | Jun 16, 2015 |  |
| Merus | Merus is a biotechnology company that discovers and develops new treatments for cancer patients. The company utilizes its proprietary Multiclonics Platform technology to advance its clinical pipeline of medicines. Merus conducts scientific research and clinical trials focused on developing novel treatments. | $77.3M | Series C | Apr 26, 2015 |  |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $20M | Series C | Jan 29, 2015 |  |
| Anokion | Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can betranslated to virtually any protein in numerous clinical indications. | $37.5M | Series A | May 09, 2014 |  |

10 of 12 investments shown.

## Co-investors
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 5 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 4 deals together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 3 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 3 deals together
- [Hyfinity Investments](https://shizune.co/investors/profile/hyfinity-investments) — VC Fund, 2 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 2 deals together

## About Amyl Therapeutics

VC Fund · Liège, Belgium

Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

4 contacts available at Amyl Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Florent Gros | Co-Founder and Chairman | https://shizune.co/investors/profile/florent-gros-4c33 |
| Florent Gros | Co-Founder and Chairman | https://shizune.co/investors/profile/florent-gros |
| Florent Gros | Co-Founder and Chairman | https://shizune.co/investors/profile/florent-gros-1ebf |
| Pierre Vandepapelière | Chief Executive Officer, Chief Medical Officer and Founder | https://shizune.co/investors/profile/pierre-vandepapeli%C3%A8re-pierre-vandepapeli%C3%A8re |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Florent Gros invest in?

Florent Gros invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 12 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Florent Gros last invest?

The most recent investment recorded for Florent Gros closed in Dec 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co